Tips for searching:
• You have to select a product and type at least 2 words to activate the search
• Use only words that are specific to the information you are looking for
• Avoid typing questions or sentences
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow card in the Google play or Apple app store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Omvoh ® ▼ (mirikizumab)
This information is intended for UK registered healthcare professionals only in response to your search for information. For current information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk
Is it normal to see air bubbles in Omvoh® (mirikizumab) pre-filled pens or syringes?
It is normal to see air bubbles in mirikizumab pre-filled pens or syringes. They will not cause harm or affect the dose.
Air bubbles and subcutaneous injections
Mirikizumab 100 mg solution for injection should only be used for the subcutaneous maintenance doses.1
Injecting air bubbles is more of a safety concern when medicines need to be injected into a vein.2
DO NOT try to remove or expel the air bubble(s) in the pre-filled pen or syringe. Removal of air bubble(s) before injecting is not necessary and is not recommended.2
References
1Omvoh [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.
2Data on file, Eli Lilly and Company and/or one of its subsidiaries.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Date of Last Review: 21 April 2023